Minakem Generic APIs Minakem Generic APIs

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"QSAM Biosciences","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"QSAM Biosciences Receives Third U.S. Patent for Clinical-Stage Radiopharmaceutical Drug Candidate CycloSam","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"QSAM Biosciences","sponsor":"Telix Pharmaceuticals","pharmaFlowCategory":"D","amount":"$125.1 million","upfrontCash":"$2.0 million","newsHeadline":"Telix Announces Proposed Acquisition of QSAM Biosciences and its Lead Therapy Candidate, CycloSam\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"QSAM Biosciences","sponsor":"Telix Pharmaceuticals","pharmaFlowCategory":"D","amount":"$123.1 million","upfrontCash":"$33.1 million","newsHeadline":"Telix Signs Agreement to Acquire QSAM Biosciences and its Bone Cancer Targeting Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by QSAM Biosciences

    Menu

    QSAM Biosciences

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              QSAM Biosciences

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Telix Signs Agreement to Acquire QSAM Biosciences and its Bone Cancer Targeting Platform

              Details:

              Through the acquisition, Telix Pharmaceuticals have access to lead investigational drug Cycloslam (samarium-153-DOTMP) for the treatment of therapeutic radiopharmaceuticals for primary and metastatic bone cancer.

              Lead Product(s): Samarium-153-DOTMP

              Therapeutic Area: Oncology Product Name: CycloSam

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Telix Pharmaceuticals

              Deal Size: $123.1 million Upfront Cash: $33.1 million

              Deal Type: Acquisition February 07, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              QSAM Biosciences

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Telix Announces Proposed Acquisition of QSAM Biosciences and its Lead Therapy Candidate, CycloSam®

              Details:

              Through the acquisition, Telix gain rights to CycloSam (samarium-153-DOTMP), a novel, de-risked clinical asset that has the potential to deliver tangible improvements of prior bone-seeking agents.

              Lead Product(s): Samarium-153-DOTMP

              Therapeutic Area: Oncology Product Name: CycloSam

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Telix Pharmaceuticals

              Deal Size: $125.1 million Upfront Cash: $2.0 million

              Deal Type: Acquisition November 13, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              QSAM Biosciences

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              QSAM Biosciences Receives Third U.S. Patent for Clinical-Stage Radiopharmaceutical Drug Candidate CycloSam

              Details:

              Patent covers both formulation and preparation of Samarium-153-DOTMP (CycloSam®), in U.S. with DOTMP kit formulations for radioisotope delivery targeting bone tumors, as well high-dosage use of radiopharmaceutical to perform bone marrow ablations.

              Lead Product(s): Samarium-153 DOTMP

              Therapeutic Area: Oncology Product Name: CycloSam

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: National Cancer Institute

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 13, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Symbiotec: Global API manufacturer, specializing in Cortico-Steroids & Steroid-Hormone APIs.
              Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
              Post Enquiry
              POST ENQUIRY